

ALTERNATE SELECTIVITY FOR BASES IN ULTRAPERFORMANCE LIQUID CHROMATOGRAPHY USING A NON-ENDCAPPED HIGH STRENGTH SILICA STATIONARY PHASE

Erin E. Chambers and Diane M. Diehl, Waters Corporation

A non-endcapped C_{18} stationary phase bonded to a 1.8 μm high strength silica (HSS) particle substrate was developed to provide different selectivities in UltraPerformance liquid chromatography (UPLC technology) separations. ACQUITY UPLC HSS C₁₈ SB (Selectivity for Bases) columns provide alternate selectivity for bases under acidic conditions and provide an additional UPLC method development tool.

INTRODUCTION

Altering selectivity plays a major role in maximizing resolution in chromatographic separations. UPLC technology improves resolution through the use of sub-2 µm particle-packed columns in a chromatographic system designed specifically for operation at the optimal linear velocities (and resulting pressures) for these particles. Combining multiple UPLC particle substrate technologies with alternate chemistries for different selectivity is a powerful tool for methods development scientists.

Waters ACQUITY UPLC HSS columns contain the only 100% silica particles designed, tested and intended for use in applications up to 15000 psi (1000 bar). The most recent addition to this family of chemistries is the ACQUITY UPLC HSS C18 SB column, which is designed to provide different selectivity for basic compounds when compared to traditional high coverage, fully endcapped C_{18} chemistries. This is because of the increased silanol activity on the silica particle surface when bonded at intermediate ligand densities with no endcapping. Example separations were developed for a mixture of basic drugs and some tricyclic antidepressants. A comparison with other sub-2 µm chemistries is also shown.

EXPERIMENTAL CONDITIONS

ACQUITY UPLC Conditions

CLICK ON PART NUMBERS FOR MORE INFORMATION

System: Waters ACQUITY UPLC System with

PDA detector

Indicated on figures; all columns tested Columns:

in the 2.1 50 mm format

Mobile Phase A: 10 mM NH₄COOH, pH 3.0

Mobile Phase B: MeOH (basic drug mixture) OR ACN

(tricyclic antidepressants)

Gradient: Indicated in figure captions

Flow-rate: 0.4 mL/min (basic drug mixture) OR

0.5 mL/min (tricyclic antidepressants)

Injection: 1 μL Temperature: 30°C

Detection: Indicated in figure captions

Sampling rate: 40 Hz

Samples: All compounds were prepared in water

at a concentration of 10-60 µg/mL




Figure 1: UPLC separation of seven basic drugs. All columns were in the 2.1 X 50 mm format. Gradient from 30–85% B in 3 min, hold at 85% B for 0.5 min, reset. UV 260 nm. Compounds: 1= aminopyrazine, 2= pindolol, 3 = labetalol, 4= quinine, 5= verapamil, 6= diltiazem, 7= amitriptyline.

RESULTS AND DISCUSSION

Figure 1 shows the separation of seven basic drug compounds on four different sub-2 μm chemistries. Note the differences in selectivity between the four columns. This is best seen with the labetalol and quinine peaks (switch in elution order on the HSS C_{18} SB column) and with verapamil and diltiazem, which are almost baseline resolved on the HSS C_{18} SB chemistry. Second, the HSS C_{18} SB column provides more retention for some extremely polar bases like aminopyrazine and pindolol. This is further illustrated in the isocratic separation of tricyclic antidepressants (Figure 2). The HSS C_{18} SB column retains these compounds much longer than the fully endcapped C_{18} stationary phase. In addition, it provides alternate selectivity and better resolves all compounds when compared to a competing non-endcapped C_{18} column.



As a result of the increase in surface silanol interactions, the ACQUITY UPLC HSS C18 SB column provides different selectivity under acidic conditions, especially for bases. When combined with the increased speed, sensitivity, and resolution of UPLC technology, this additional bonded phase provides another powerful tool for rapid and robust method development.




Figure 2: UPLC separation of tricyclic antidepressants. All columns were in the 2.1 X 50 mm format. Isocratic separation at 40% B. UV 254 nm. Compounds 1= trimethoprim, 2= nordoxepin, 3= doxepin, 4= nortriptyline, 5= imipramine, 6= amitriptyline, 7= trimipramine.

Austria and European Export (Central South Eastern Europe, CIS and Middle East) 43 1 877 18 07, Australia 61 2 9933 1777, Belgium 32 2 726 1000, Brazil 55 11 4134 3788, Canada 1 800 252 4752 x2205, China 86 21 6879 5888, CIS/Russia +497 727 4490/290 9737, Czech Republic 420 2 617 1 1384, Denmark 45 46 59 8080, Finland 358 9 5659 6288, France 33 130 48 72 00, Germany 49 6196 400600, Hong Kong 852 29 64 1800, Hungary 36 1 335 5086, India and India Subcontinent 91 80 2837 1900, Ireland 353 1 448 1500, Italy 39 02 265 0983, Japan 81 3 3471 7191, Korea 82 2 6300 4800, Mexico 52 55 5524 7636, The Netherlands 31 76 508 7200, Norway 47 6 384 60 50, Poland 48 22 833 4400, Puerto Rico 1 787 747 8445, Singapore 65 6273 7997, Spain 34 93 600 9300, Sweden 46 8 555 11 500, Switzerland 41 56 676 70 00, Taiwan 886 2 2543 1898, United Kingdom 44 208 238 6100, All other countries: Waters Corporation U.S.A. 1 508 478 2000/1 800 252 4752

Waters

THE SCIENCE OF WHAT'S POSSIBLE.™

UKAS QUALITY MANAGEMENT

© 2009 Waters Corporation. Waters, The Science of What's Possible, UPLC and ACQUITY UPLC are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

March 2009 720002460EN KK-PDF

Waters Corporation 34 Maple Street Milford, MA 01757 U.S.A. T: 1 508 478 2000

F: 1 508 872 1990 www.waters.com